Nasdaq GlobeNewswire

RedHill Biopharma Prices Public Offering of its American Depositary Shares

Del

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 08, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases and cancer, today announced the pricing of its previously announced underwritten public offering for a total number of 4,090,909 American Depositary Shares ("ADSs"), each representing ten of its ordinary shares, at a public offering price of $5.50 per ADS.

Gross proceeds from the sale of the ADSs by RedHill before underwriting discounts and commissions and other offering expenses are expected to be approximately $22.5 million. The offering is expected to close on November 13, 2017, subject to customary closing conditions. RedHill has also granted the underwriters a 30-day option to purchase up to 613,636 additional ADSs at the public offering price.
            
Cantor Fitzgerald & Co. and Nomura Securities International, Inc. are acting as joint book-running managers for the offering. SMBC Nikko Securities America, Inc. is acting as lead manager and H.C. Wainwright & Co., LLC and Roth Capital Partners, LLC are acting as co-managers for the offering.

The Company intends to use the proceeds from the offering to fund clinical development programs, for potential acquisitions, to support commercial operations and for general corporate purposes.

The ADSs described above are being offered by RedHill pursuant to a shelf registration statement that was previously filed with the Securities and Exchange Commission (the "SEC") and declared effective by the SEC on March 11, 2016. A preliminary prospectus supplement related to the public offering has been filed with the SEC and is available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, by contacting Cantor Fitzgerald & Co, Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by e-mail at prospectus@cantor.com, or Nomura Securities International, Inc., Attention: Equity Syndicate Department, Worldwide Plaza, 309 West 49th Street, New York, NY 10019-7316 or by telephone at 212-667-9000 or by email at equitysyndicateamericas@nomura.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) is a specialty biopharmaceutical company, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill promotes three gastrointestinal products in the U.S. and its clinical stage pipeline includes treatments for gastrointestinal indications, pancreatic cancer and acute migraines:  Donnatal ®   -  a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis;  Esomeprazole Strontium   Delayed-Release Capsules 49.3 mg -   a prescription proton pump inhibitor indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal conditions; and  EnteraGam ®  - a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. RedHill's clinical-stage pipeline includes: (i)  TALICIA (TM)   (RHB -105)   -  an oral combination therapy for the treatment of  Helicobacter pylori  infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; (ii)  RHB-104   -  an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and a planned pivotal Phase III study for nontuberculous mycobacteria (NTM) infections; (iii)  BEKINDA ®   (RHB-102)   -  a once-daily oral pill formulation of ondansetron with successful top-line results from a Phase III study in acute gastroenteritis and gastritis and successful top-line results from a Phase II study in IBS-D; (iv)  RHB-106   -  an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v)  YELIVA ®   (ABC294640)   -  a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi)  MESUPRON -   a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and inflammatory gastrointestinal diseases and (vii)   RIZAPORT ®   (RHB-103) -  an oral thin-film formulation of rizatriptan for acute migraines, with a U.S. NDA resubmitted to the FDA and marketing authorization received in two EU member states under the European Decentralized Procedure (DCP).

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, preclinical studies, clinical trials and other therapeutic candidate development efforts; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization and market acceptance of the Company's therapeutic candidates; (v) the Company's ability to successfully market Donnatal ®   and EnteraGam ® ; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program,; and (xiv) competition from other companies and technologies within the Company's industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the SEC, including the Company's Annual Report on Form 20-F filed with the SEC   on February 23, 2017. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.

Company contact:
Adi Frish
Senior VP Business Development & Licensing 
RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com
IR contact (U.S.):  
Marcy Nanus
Senior Vice President
The Trout Group
+1-646-378-2927
Mnanus@troutgroup.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: RedHill Biopharma Ltd. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

The IASLC 19th World Conference on Lung Cancer Arrives in Toronto, Canada21.8.2018 18:43Pressemelding

DENVER, Aug. 21, 2018 (GLOBE NEWSWIRE) -- What: The International Association for the Study of Lung Cancer (IASLC) presents the IASLC 19th World Conference on Lung Cancer (WCLC) on September 23-26, 2018, in Toronto, Canada. The WCLC is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, and is expected to convene over 7,000 researchers, physicians, specialists, patients, advocates and industry members from around the world. The WCLC’s scientific program features a line-up of global leaders in the field. Presentations focus on cutting-edge science, including the latest breakthroughs in targeted therapies and immunotherapies; advances in screening, early detection and staging; prevention and smoking cessation efforts; patient advocacy initiatives; and much more. Collaboration across disciplines and borders is a meeting highlight. The WCLC’s scientific program is available to review online. When and Where: September 23-26, 2018, Metro Toronto Conve

TrueCommerce Announces Microsoft Dynamics 365 Business Central Integration21.8.2018 16:00Pressemelding

End-to-end, cloud-based EDI solution offers immediate connectivity with retailers, marketplaces, dropship vendor programs and ecommerce storefronts PITTSBURGH, Aug. 21, 2018 (GLOBE NEWSWIRE) -- TrueCommerce, a global provider of trading partner connectivity and integration solutions, today announced its integration with Microsoft Dynamics 365 Business Central, an all-in-one business management solution for small to midsize companies. The new TrueCommerce integration makes it simple and affordable for organizations on the Business Central platform to connect and integrate their sales channels and streamline fulfillment. “The Microsoft Dynamics 365 Business Central platform offers an end-to-end view of sales, purchasing, inventory and customer interactions within one platform,” said TrueCommerce president Ross Elliott. “TrueCommerce extends that view outside the four walls of an enterprise by integrating sales, purchasing, inventory, and fulfillment interactions with supply chain partici

Kasha Cacy Appointed Global CEO of Engine21.8.2018 14:30Pressemelding

NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Data-driven marketing solutions company Engine today announced the appointment of Kasha Cacy as the company’s global chief executive officer, a new position. Effective Sept. 4, Cacy will oversee Engine’s 17 offices across North America, the UK, Europe and Asia-Pacific, leading the company’s marketing solutions offering, from insights and content to distribution and technology. Cacy joins Engine from UM, the full-service marketing and media agency network of IPG Mediabrands, where she served as U.S. CEO. She will be based out of Engine’s headquarters in New York, and will report to Engine Executive Chairman Paul Caine. “I’m delighted to welcome Kasha to the Engine family,” said Caine. “Her talent, drive and vision will be tremendous assets as we enter an exciting time for the company and our clients. Kasha has deep expertise across media, data, marketing and consulting. She will be key in leading Engine as we build upon our differentiated offe

SoftServe Heats Up the Cloud Market with New Dedicated Go-to-Market Strategy with Google Cloud21.8.2018 13:00Pressemelding

AUSTIN, Texas, Aug. 21, 2018 (GLOBE NEWSWIRE) -- SoftServe, a digital authority and consulting company, announces a new go-to-market strategy with Google Cloud, as part of SoftServe’s recent acknowledgement as a Google Cloud Premier Partner. SoftServe joined the Google Cloud Partner Program in April 2017 and has since completed extensive technical training, successfully delivered numerous complex implementations on GCP and met rigorous evaluations to achieve Google Cloud’s highest partner status. “As part of the growing Google Cloud partner ecosystem, achieving the Premier status is a testament to SoftServe’s commitment to innovation that moves the needle for our clients every day on their digital journey,” said Todd Lenox, Vice President, Digital Services Group at SoftServe. “Our continued partnership with Google Cloud enables us to provide cutting-edge cloud expertise for the future.” As part of the premier partnership, SoftServe is heating up the cloud market by executing well-coord

SolarWinds Broadens Systems Portfolio with Unified Infrastructure Management Enhancements21.8.2018 12:30Pressemelding

Portfolio enhancements to be showcased at VMworld 2018 US AUSTIN, Texas, Aug. 21, 2018 (GLOBE NEWSWIRE) -- SolarWinds, a leading provider of powerful and affordable IT management software, today unveiled a wave of updates to the SolarWinds® Orion® Platform and its product portfolio. The enhancements span multiple products, with SolarWinds debuting the latest versions of Server & Application Monitor (SAM), Virtualization Manager (VMAN), Storage Resource Monitor (SRM), and introducing SolarWinds Server Configuration Monitor (SCM). The enhancements enable unified infrastructure management for technology practitioners, designed to help them quickly identify performance issues and correlations between all layers of the technology stack. “Technology professionals managing increasingly complex and distributed IT environments require monitoring tools that transcend the challenges introduced by hybrid IT,” said Christoph Pfister, executive vice president of products, SolarWinds. “The portfolio

Bombardier Wins Contract to Provide up to 50 TRAXX MS3 Locomotives to CD Cargo21.8.2018 12:21Pressemelding

Order marks the TRAXX 3 platform’s arrival in the Central, Eastern and Southeastern European markets First call off for 10 high-performance TRAXX Multi-System locomotives will strengthen hauling capacity and reduce energy consumption BERLIN, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Note to editors: To view the photos associated with this press release, please visit the following links: http://www.globenewswire.com/NewsRoom/AttachmentNg/6de34b48-f11a-498d-9865-4deb67548b01 http://www.globenewswire.com/NewsRoom/AttachmentNg/fb82fb71-44cf-48c2-aa37-1d277fd35ae8 Rail technology leader, Bombardier Transportation and CD Cargo, the freight subsidiary of Czech Railways, have signed a purchase agreement for up to 50 of the newest generation of BOMBARDIER TRAXX Multi-System1 (MS) locomotives. This first call-off is for 10 TRAXX MS3 locomotives. Ivan Bednárik, Chairman of the Board of Directors, CD Cargo, said, “The new TRAXX MS3 locomotive will be the most modern in our fleet. Its powerful traction and

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom